FDA Approved: TURALIO — Original Application (Daiichi Sankyo Inc.)

View source ↗

Summary

The FDA approved TURALIO (pexidartinib hydrochloride) in support of the original NDA for the treatment of tenosynovial giant cell tumor (TGCT).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tenosynovial Giant Cell Tumor

Drugs mentioned

• TURALIO (pexidartinib)

Snippet

ORIG AP for TURALIO (PEXIDARTINIB HYDROCHLORIDE)